- •Women with risk factors for cardiovascular disease may still be good candidates for hormone therapy.
- •Transdermal routes of hormone therapy are preferred for women with moderate to severe menopausal symptoms and cardiovascular risk factors.
- •The treatment of genitourinary syndrome of menopause with low-dose vaginal estrogen or other local vaginal therapy is safe in women with risk factors for cardiovascular disease and in women with a history of heart attack or stroke.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Maturitas
Worlddata.info https://www.worlddata.info/life-expectancy.php accessed 4/17/2021.
- Menopause Practice: A Clinician's Guide.6th ed. NAMS, Mayfield Heights (OH)2019
- Duration of menopausal vasomotor symptoms over the menopause transition.JAMA Intern. Med. 2015; 175: 531-539
NAMS position statement: the 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. Menopause Vol 27, No 9, pp 976–992.
- Menopausal symptoms and their management.Endocrinol. Metab. Clin. N. Am. 2015; 44: 497-515
- Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society.Menopause. 2021; 17: 25-54
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.JAMA. 2002; 288: 321-333
- Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials.JAMA. 2017; 318: 927-938
- Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone verse placebo: the Kronos Early Estrogen Prevention Study.Menopause. 2017; 24: 238-246
- Vascular effects of early versus late postmenopausal treatment with estradiol.N. Engl. J. Med. 2016; 374: 1221-1231
- Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.Lancet. 2003; 362: 428-432
- Menopausal hormone therapy and cardiovascular disease: the role of formulation, dose, and route of delivery.J. Clin. Endocrinol. Metab. 2021; 106: 1245-1254
- Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study.J. Thromb. Haemost. 2006; 4: 1259-1265
- Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.BMJ. 2008; 336
- Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial.BMJ. 2012; : 345
- The 2017 hormone therapy position statement of the North American Menopause Society.Menopause. 2017; 24 (28): 728-753
- Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline.J. Clin. Endocrinol. Metab. 2015; 100: 3975-4011
- Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism.Obstet. Gynecol. 2013; 121: 887-890
- 2016 IMS Recommendations on women's midlife health and menopause hormone therapy.Climacteric. 2016; 19: 109-150
- EMAS position statement: the ten-point guide to the integral management of menopausal health.Maturitas. 2015; 81: 88-92
- Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women's health initiative randomized trials.JAMA. 2017; 318: 927-938
- Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women.Circulation. 1996; 93: 1928-1937
- Gender differences in epidemiology, pathophysiology, and treatment of hypertension.Curr. Atheroscler. Rep. 2018; 20: 13
- Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of the North American Menopause Society.Menopause. 2015; 22 (quiz 1173-4): 1155-1172
- SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials.J. Gen. Intern. Med. 2014; 29: 204-213
- QT prolongation, torsades de pointes, and psychotropic medications: a 5-year update.Psychosomatics. 2018; 59: 105-122
- Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial.Menopause. 2008; 15: 310-318
- Oxybutynin for refractory hot flashes in cancer patients.Menopause. 2007; 14: 505-509
- Transdermal clonidine for ameliorating tamoxifen-induced hot flashes.J. Clin. Oncol. 1994; 12 (39): 155-158
- Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study.Ann. Intern. Med. 2000; 132: 788-793
- Non-hormonal interventions for hot flushes in women with a history of breast cancer.Cochrane Libr. 2010; (CD004923)
- Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence.Climacteric. 2021; 24: 109-119
- Why the product labeling for low-dose vaginal estrogen should be changed.Menopause. 2014; 21: 911-916
- Menopausal hormone therapy and 20-year breast cancer mortality.Lancet. 2019; 394 (Epub 2019 Aug 29): 1139https://doi.org/10.1016/S0140-6736(19)32033-1
- The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society.Menopause. 2020; 27 (The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020 Sep;27(9):976-992): 976-992
- Safety of vaginal estrogens: a systematic review.Menopause. 2020; 27: 339-360
- Hypertension in women.Hypertension. 2017; 70: 19-26
- Metabolic syndrome, and menopause: pathophysiology, clinical and diagnostic significance.Adv. Clin. Chem. 2015; 72: 1-75
- Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension.Hypertension. 2006; 48: 246-253
European Society of Cardiology (https://www.escardio.org/Education/Diabetes-and-CVD/Recommended-Reading/global-statistics-on-diabetes) Accessed 4/2021.j.
- Menopause, hormone therapy and diabetes.Climacteric. 2017; 20 (Epub 2017 Jan 8): 11-21https://doi.org/10.1080/13697137.2016.1267723
- 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation. 2019; 140
- Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events.Am. J. Cardiol. 2008; 101: 1599-1605
- Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS).Am. Heart J. 2003; 146: 870-875
World Health Organization (https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight) Accessed 4/2021.
- The global epidemic of the metabolic syndrome.Curr. Hypertens. Rep. 2018; 20 (PMID: 29480368; PMCID: PMC5866840): 12https://doi.org/10.1007/s11906-018-0812-z
- Metabolic syndrome.J. Cardiovasc. Pharmacol. Ther. 2017; 22: 365-367
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.JAMA. 2002; 288: 321-333
- Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members.Genet. Med. 2011; 13: 67-76
- Oral contraceptives and HRT risk of thrombosis.Clin. Appl. Thromb. Hemost. 2018; 24: 217-225
- Migraine, menopause and hormone replacement therapy.Post Reprod. Health. 2018; 24: 11-18
- Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy.Heart. 2019; 105: 1273-1278
- Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes.Diabet. Med. 2004 Feb; 21: 103-113
- Preterm delivery and maternal cardiovascular disease risk factors: the Nurses' Health Study II.J. Womens Health (Larchmt). 2019; 28: 677-685
- Cardiovascular disease in menopause: does the obstetric history have any bearing?.Menopause Int. 2013; 19: 115-120
- Menopausal hormone therapy and cardiovascular risk: where are we now?.Curr. Vasc. Pharmacol. 2019; 17: 564-572